GlaxoSmithKline PLC (LON:GSK) Rating Reaffirmed
The rating of GlaxoSmithKline PLC (LON:GSK) shares were has decided to reaffirm by analysts at Beaufort Securities. This was shown in a comprehensive report on Monday, 21 December.
From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1477.54 with a 9.50% above today’s (GBX 1345.5) stock price. GlaxoSmithKline PLC was the topic of 100 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Beaufort Securities maintained shares on December 21 with “Buy” rating. Jefferies maintained shares with “Hold” rating and GBX 1325 target share price in a report from a December 7. Morgan Stanley maintained GSK stock in a recent report from December 18 with “Equalwt/In-Line” rating. Liberum Capital maintained the rating on December 3. Liberum Capital has a “Hold” rating and a GBX 1350 price target on shares. Finally, BNP Paribas maintained the stock with “Neutral” rating in a report issued on a December 9.
Approximately 394,482 shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 8.91% since May 22, 2015 and is downtrending. It has underperformed by 3.10% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 65.48 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.62 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”